STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Completed
GlaxoSmithKline
Phase 4
2008-06-01
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June
2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in
immunocompetent patients 12 years of age and older. The approved dosing regimen is twice
daily for 4 weeks. The treatment of recurrent seborrheic dermatitis demands a topical
preparation that is safe for both short-term and chronic application. This study is being
conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam,
2% in the treatment of seborrheic dermatitis.
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Completed
Stiefel, a GSK Company
Phase 4
2008-06-01
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June
2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in
immunocompetent patients 12 years of age and older. The approved dosing regimen is twice
daily for 4 weeks. The treatment of recurrent seborrheic dermatitis demands a topical
preparation that is safe for both short-term and chronic application. This study is being
conducted in order to obtain long-term safety data on the use of Extina (ketoconazole) Foam,
2% in the treatment of seborrheic dermatitis.
Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo
Completed
St. Louis University
N/A
2010-09-01
The aims of this study are to compare the effectiveness of antifungal foam versus antifungal
shampoo and determine patient compliance and satisfaction with both vehicles among African
American females with dandruff practicing less than once weekly hair washing.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
